Shanghai Haoyuan Chemexpress Co. Ltd. A Cash Flow Conversion Efficiency
Shanghai Haoyuan Chemexpress Co. Ltd. A cash flow conversion efficiency. Based on the latest financial reports, Shanghai Haoyuan Chemexpress Co. Ltd. A (688131) has a cash flow conversion efficiency ratio of 0.034x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥107.21 Million ≈ $15.69 Million USD) by net assets (CN¥3.13 Billion ≈ $458.54 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Shanghai Haoyuan Chemexpress Co. Ltd. A (2013–2025)
Cash flow conversion efficiency of Shanghai Haoyuan Chemexpress Co. Ltd. A from 2013 to 2025. This chart illustrates how Shanghai Haoyuan Chemexpress Co. Ltd. A's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 688131 stock price for real-time trading data and today's change.
Shanghai Haoyuan Chemexpress Co. Ltd. A Cash Flow Conversion Ratio Explained
Shanghai Haoyuan Chemexpress Co. Ltd. A cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Shanghai Haoyuan Chemexpress Co. Ltd. A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Haoyuan Chemexpress Co. Ltd. A ranked by their cash flow conversion efficiency. Also see Shanghai Haoyuan Chemexpress Co. Ltd. A (688131) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Anhui Expressway Co Ltd
SHG:600012
|
0.072x |
|
Ideaya Biosciences Inc
NASDAQ:IDYA
|
-0.136x |
|
National Storage REIT
AU:NSR
|
0.018x |
|
Cal-Maine Foods Inc
NASDAQ:CALM
|
0.002x |
|
AIR CHINA LTD H ADR/20
F:AD2B
|
N/A |
|
Virbac SA
PA:VIRP
|
0.023x |
|
Vidrala SA
MC:VID
|
0.048x |
|
Tarsus Pharmaceuticals Inc
NASDAQ:TARS
|
0.193x |
Annual Cash Flow Conversion Efficiency for Shanghai Haoyuan Chemexpress Co. Ltd. A (2013–2025)
The table below shows the annual cash flow conversion efficiency of Shanghai Haoyuan Chemexpress Co. Ltd. A from 2013 to 2025. Review free cash flow generation of Shanghai Haoyuan Chemexpress Co. Ltd. A to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥9.43 Billion ≈ $1.38 Billion |
CN¥317.75 Million ≈ $46.50 Million |
0.034x | -74.37% |
| 2024-12-31 | CN¥2.90 Billion ≈ $424.98 Million |
CN¥381.96 Million ≈ $55.89 Million |
0.132x | +633.61% |
| 2023-12-31 | CN¥2.53 Billion ≈ $369.67 Million |
CN¥-62.27 Million ≈ $-9.11 Million |
-0.025x | +76.07% |
| 2022-12-31 | CN¥2.33 Billion ≈ $341.24 Million |
CN¥-240.23 Million ≈ $-35.15 Million |
-0.103x | -427.11% |
| 2021-12-31 | CN¥1.84 Billion ≈ $268.73 Million |
CN¥57.83 Million ≈ $8.46 Million |
0.031x | -85.77% |
| 2020-12-31 | CN¥527.81 Million ≈ $77.24 Million |
CN¥116.79 Million ≈ $17.09 Million |
0.221x | +54.98% |
| 2019-12-31 | CN¥399.73 Million ≈ $58.49 Million |
CN¥57.07 Million ≈ $8.35 Million |
0.143x | -10.78% |
| 2018-12-31 | CN¥177.65 Million ≈ $26.00 Million |
CN¥28.43 Million ≈ $4.16 Million |
0.160x | +72.73% |
| 2017-12-31 | CN¥114.74 Million ≈ $16.79 Million |
CN¥10.63 Million ≈ $1.56 Million |
0.093x | +143.20% |
| 2016-12-31 | CN¥56.86 Million ≈ $8.32 Million |
CN¥-12.19 Million ≈ $-1.78 Million |
-0.214x | -484.77% |
| 2015-12-31 | CN¥32.65 Million ≈ $4.78 Million |
CN¥1.82 Million ≈ $266.30K |
0.056x | +146.55% |
| 2014-12-31 | CN¥33.10 Million ≈ $4.84 Million |
CN¥-3.96 Million ≈ $-579.94K |
-0.120x | -197.57% |
| 2013-12-31 | CN¥9.70 Million ≈ $1.42 Million |
CN¥1.19 Million ≈ $174.12K |
0.123x | -- |
About Shanghai Haoyuan Chemexpress Co. Ltd. A
Shanghai Haoyuan Chemexpress Co., Ltd. researches, develops, and manufactures pharmaceutical intermediates and small molecule drugs. The company offers APIs and API intermediates, vitamin D series compounds, CRO building blocks, and CRO life bioscience compounds. The company was founded in 2006 and is headquartered in Shanghai, China.